Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹1,539 Cr
up ₹76 Cr vs Jun 2016
- Stocks held
- 18
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In July 2016 it disclosed 18 stocks worth ₹1,539 Cr, up ₹76 Cr from Jun 2016. Its largest positions were Abbott India Limited (10.7%), Sun Pharmaceutical Industries Limited (10.0%), Sanofi India Limited (9.4%); the ten largest together made up 81.3% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 89.4% of its equity. Cash and debt stood at 3.6%. Compared with Jun 2016 the fund entered 1 new stock and exited 1.
Against 227 other Sectoral / Thematic funds
Concentration
99%
Top-10 weight is higher than 99% of peers
Breadth
4%
Holds more stocks than 4% of peers
Cash
54%
Holds more cash than 54% of peers
Holdings in July 2016
Download CSVEvery line the fund disclosed, with the change against Jun 2016. Click a column to sort; click a company to see every fund that owns it.
| Abbott India Limited | 10.69% | down 0.43 pts | ₹165 Cr | up ₹1.8 Cr | Added |
| Sun Pharmaceutical Industries Limited | 9.96% | up 0.33 pts | ₹153 Cr | up ₹12.3 Cr | Added |
| Sanofi India Limited | 9.43% | down 0.24 pts | ₹145 Cr | up ₹3.7 Cr | Added |
| Cipla Limited | 9.25% | up 0.01 pts | ₹142 Cr | up ₹7.1 Cr | Added |
| Divi's Laboratories Limited | 8.97% | down 0.15 pts | ₹138 Cr | up ₹4.7 Cr | Added |
| Aurobindo Pharma Limited | 7.80% | down 0.41 pts | ₹120 Cr | down ₹0 L | Held |
| Lupin Limited | 7.70% | down 0.52 pts | ₹119 Cr | down ₹1.8 Cr | Trimmed |
| Zydus Lifesciences Limited | 7.39% | up 0.44 pts | ₹114 Cr | up ₹12 Cr | Added |
| IPCA Laboratories Limited | 5.68% | up 0.02 pts | ₹87.4 Cr | up ₹4.6 Cr | Added |
| Thyrocare Technologies Limited | 4.40% | up 1.32 pts | ₹67.7 Cr | up ₹22.7 Cr | Added |
| Cash, TREPS & receivables | 3.59% | up 3.00 pts | ₹55.3 Cr | up ₹46.5 Cr | Added |
| Biocon Limited | 3.23% | down 0.06 pts | ₹49.8 Cr | up ₹1.6 Cr | Added |
| FDC Limited | 2.87% | down 0.85 pts | ₹44.2 Cr | down ₹10.2 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 2.40% | down 3.98 pts | ₹36.9 Cr | down ₹56.3 Cr | Trimmed |
| Max India Limited | 1.72% | up 1.72 pts | ₹26.5 Cr | up ₹26.5 Cr | New |
| Indoco Remedies Limited | 1.70% | up 0.03 pts | ₹26.1 Cr | up ₹1.8 Cr | Added |
| Healthcare Global Enterprises Limited | 1.50% | up 0.19 pts | ₹23.1 Cr | up ₹3.8 Cr | Added |
| Narayana Hrudayalaya Limited | 0.95% | up 0.15 pts | ₹14.6 Cr | up ₹2.9 Cr | Added |
| Alkem Laboratories Limited | 0.77% | down 0.18 pts | ₹11.8 Cr | down ₹2.1 Cr | Trimmed |
What changed, Jun 2016 to Jul 2016
New New positions (1)
- Max India Limited1.7% · ₹26.5 Cr
Exited Exited (1)
- Syngene International Limitedwas 0.4% · ₹5.6 Cr
Added Biggest additions
- Thyrocare Technologies Limitedup ₹22.7 Cr (+1.32% pts)
- Sun Pharmaceutical Industries Limitedup ₹12.3 Cr (+0.33% pts)
- Zydus Lifesciences Limitedup ₹12 Cr (+0.44% pts)
- Cipla Limited
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jun 2016, the weight rose most in Healthcare Services (+3.3 pts), and fell most in Pharmaceuticals & Biotechnology (−3.4 pts).
- Healthcare Services5.6% → 8.9%+3.3 pts
- Pharmaceuticals & Biotechnology92.7% → 89.4%−3.4 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jul 2013 | Jul 2015 | Jan 2016 | Apr 2016 | Jun 2016 | Jul 2016 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 82.3% | 95.6% | 96.2% | 96.5% | 92.7% | 89.4% |
| Healthcare Services | 0.8% | 1.5% | 1.8% | 1.8% | 5.6% | 8.9% |
| Pharmaceuticals | 11.9% | 2.9% | 2.0% | 1.6% | 1.7% | 1.8% |
Allocation in Jul 2016change vs Jun 2016
- Pharmaceuticals & Biotechnology (13)89.4%▼ 3.4 pts
- Healthcare Services (4)8.9%▲ 3.3 pts
- Pharmaceuticals (1)1.8%▲ 0.1 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal.
Cash & debt, Jul 2016
3.6%
▲ 3.0 pts vs Jun 2016
- Cash alone
- 3.6%
- cash and net receivables
- A year earlier
- 1.9%
- Jul 2015 · now ▲ 1.7 pts
- Last 12 months
- 0.6% – 9.6%
- lowest to highest · record 9.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.